FINWIRES · TerminalLIVE
FINWIRES

BriaCell Therapeutics Adds New Clinical Site For Phase 3 Bria-ABC Study

By

-- BriaCell Therapeutics (BCT.TO) has added NYU Langone Health's Laura and Isaac Perlmutter Cancer Center, as a clinical trial site in its ongoing Phase 3 clinical study, the company said on Thursday.

The Phase 3 clinical study in advanced breast cancer (Bria-ABC) is evaluating the company's lead clinical candidate, Bria-IMT, plus an immune check point inhibitor in advanced metastatic breast cancer.

Interim analysis of the Phase 3 study will be conducted after 144 patient events (deaths) have occurred, with overall survival (OS) as the primary endpoint.

The Bria-IMT combination regimen has also been granted FDA Fast Track designation.

BriaCell shares were last seen up US$0.033, to US$4.183, in U.S. pre-market trading.

Related Articles

Mining & Metals

RBC Maintains Suncor Energy's Outperform Rating, C$100 Price Target

RBC Capital Markets on Wednesday reiterated Suncor Energy's (SU.TO) outperform rating and C$100 price target, with the bank noting the company delivered another quarter of "robust performance" punctuated by a "jumbo-sized" downstream pre-tax margin of $2 billion (including FIFO gains) in part driven by record refined product sales of 680,900 bbl/d.RBC's updated production outlook of 862,100 bbl/d, anchored by a $5.7 billion capital program, remains relatively unchanged."Suncor's first-quarter results reinforced our confidence that its culture of sustained high performance is taking deep root and enabling the company to be on the podium, come what may," RBC said. "We believe the ingredients are in place for the company to earn a premium relative valuation, conceivably over the next year," RBC added.Suncor is RBC's favorite integrated producer in Canada and is part of its Global Energy Best Ideas list.Suncor traded at $85.70 per share at last look Thursday on the Toronto Stock Exchange.Price: $85.70, Change: $-2.21, Percent Change: -2.51%

$SU.TO
Australia

RBC Capital Adjusts VSE Price Target to $240 From $220, Maintains Outperform Rating

VSE (VSEC) has an average rating of Buy and mean price target of $248.50, according to analysts polled by FactSet.Price: $206.85, Change: $-0.60, Percent Change: -0.29%

$VSEC
Australia

RBC Capital Adjusts United Therapeutics Price Target to $701 From $707, Maintains Outperform Rating

United Therapeutics (UTHR) has an average rating of buy and mean price target of $670.67, according to analysts polled by FactSet.Price: $585.63, Change: $-11.14, Percent Change: -1.87%

$UTHR